2020 American Transplant Congress
Single Center Experience of Valganciclovir and Adjunctive CMV IVIG for the Treatment of CMV Infection in Lung Transplant Recipients
*Purpose: Cytomegalovirus(CMV) infection happens commonly and causes significant morbidity in lung transplant (LTx) recipients. The use of CMV hyperimmune globulin (CMVIg) as an adjunctive treatment…2020 American Transplant Congress
Letermovir Treatment for Established Cytomegalovirus Infection in Transplant Recipients
*Purpose: The purpose of the study was to describe the patterns of use and clinical/virologic outcomes of letermovir treatment for established CMV infection in transplant…2020 American Transplant Congress
Comparison of Prophylaxis Strategies for CMV Infection in Liver Transplant Recipients
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: The best strategy to prevent cytomegalovirus (CMV) following liver transplantation is not defined for intermediate risk recipients (recipient seropositive (R+) regardless of donor status).…2020 American Transplant Congress
Epidemiology Cytomegalovirus Infection/Disease in Kidney Transplant Recipients: A Systematic Review of Observational Studies
1Merck & Co., Inc., Kenilworth, NJ, 2Evidera, Inc., Waltham, MA, 3Tufts Medical Center, Boston, MA
*Purpose: Efficacy of several CMV anti-viral strategies has been shown in controlled trials for CMV infection/disease in kidney transplant recipients (KTRs). However, a comprehensive analysis…2020 American Transplant Congress
Cytomegalovirus Infection and Disease in Pediatric Liver Transplantation: Burden of Disease Under a Preemptive Therapy Approach
Transplant Department, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico
*Purpose: To report the incidence cytomegalovirus (CMV) infection (CMV-I) and disease (CMV-D) in a cohort of pediatric liver transplant recipients under preemptive therapy, identify risk…2020 American Transplant Congress
Cytomegalovirus Preemptive Monitoring Conversion and the Use of a Preemptive Threshold after Solid Organ Transplant
*Purpose: Cytomegalovirus (CMV) in solid organ transplant (SOT) is associated with negative graft and patient outcomes. Prophylactic agents of choice have substantial cytotoxicity, and patients…2020 American Transplant Congress
Pharmacist Management after Preemptive Monitoring Conversion as a Component of a Cytomegalovirus Antiviral Stewardship Program at a Large Transplant Center
*Purpose: Cytomegalovirus (CMV) in solid organ transplant (SOT) is associated with negative graft and patient outcomes. Prophylactic agents of choice have substantial cytotoxicity, and patients…2020 American Transplant Congress
Low Level CMV Detection and Effectiveness of Low Dose Valganciclovir Prophylaxis in Intermediate-Risk Liver Transplant Recipients
*Purpose: The purpose of this study is to assess the efficacy of low dose (450 mg/day) valganciclovir in preventing CMV infection in intermediate-risk liver transplant…2020 American Transplant Congress
Evaluation of Cytomegalovirus Prophylaxis in Low and Intermediate Risk Kidney Transplant Recipients Receiving Lymphocyte-Depleting Induction
Hartford Hospital, Hartford, CT
*Purpose: This study evaluates if choice and duration of Cytomegalovirus (CMV) prophylaxis based on donor (D) and recipient (R) CMV serostatus impacts the incidence of…2020 American Transplant Congress
T Cell Dysfunction as Measured by Impaired Antigen Response is Associated with Infection and Frailty in Kidney Transplant Recipients
David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Kidney transplant recipients are at risk for infection, especially the growing numbers of older patients. Our previous studies demonstrated that senescent and exhausted T…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 33
- Next Page »